Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure.

Female Humans Male Acute-On-Chronic Liver Failure / diagnosis Prognosis Hepatitis, Autoimmune / complications End Stage Liver Disease / complications Severity of Illness Index Prednisolone / therapeutic use Retrospective Studies

AARC score Acute-on-chronic liver failure Autoimmune hepatitis MELD score SURFASA score

Journal

Hepatology international

ISSN: 1936-0541

Titre abrégé: Hepatol Int

Pays: United States

ID NLM: 101304009

Informations de publication

Date de publication:
Aug 2023

Historique:

received: 12 09 2022

accepted: 06 01 2023

medline: 31 7 2023

pubmed: 16 2 2023

entrez: 15 2 2023

Statut: ppublish

Résumé

Early identification of non-response to steroids is critical in patients with autoimmune hepatitis (AIH) causing acute-on-chronic liver failure (ACLF). We assessed if this non-response can be accurately identified within first few days of treatment. Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [- 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks. Fifty-five out of one hundred and sixty-five patients (age-38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22-27); median AARC score 7 (6-9)] given oral prednisolone 40 (20-40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754-0.93)], MELD [0.837 (95% CI 0.733-0.94)] score and SURFASA score [0.795 (95% CI 0.678-0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687-0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ - 1.2, could identify non-responders at day 3 (concomitant- 75% vs either - 42%, p < 0.001). Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE

METHODS METHODS

Patients with AIH-ACLF without baseline infection/hepatic encephalopathy were identified from APASL ACLF research consortium (AARC) database. Diagnosis of AIH-ACLF was based mainly on histology. Those treated with steroids were assessed for non-response (defined as death or liver transplant at 90 days for present study). Laboratory parameters, AARC, and model for end-stage liver disease (MELD) scores were assessed at baseline and day 3 to identify early non-response. Utility of dynamic SURFASA score [- 6.80 + 1.92*(D0-INR) + 1.94*(∆%3-INR) + 1.64*(∆%3-bilirubin)] was also evaluated. The performance of early predictors was compared with changes in MELD score at 2 weeks.

RESULTS RESULTS

Fifty-five out of one hundred and sixty-five patients (age-38.2 ± 15.0 years, 67.2% females) with AIH-ACLF [median MELD 24 (IQR: 22-27); median AARC score 7 (6-9)] given oral prednisolone 40 (20-40) mg per day were analyzed. The 90 day transplant-free survival in this cohort was 45.7% with worse outcomes in those with incident infections (56% vs 28.0%, p = 0.03). The AUROC of pre-therapy AARC score [0.842 (95% CI 0.754-0.93)], MELD [0.837 (95% CI 0.733-0.94)] score and SURFASA score [0.795 (95% CI 0.678-0.911)] were as accurate as ∆MELD at 2 weeks [0.770 (95% CI 0.687-0.845), p = 0.526] and better than ∆MELD at 3 days [0.541 (95% CI 0.395, 0.687), p < 0.001] to predict non-response. Combination of AARC score > 6, MELD score > 24 with SURFASA score ≥ - 1.2, could identify non-responders at day 3 (concomitant- 75% vs either - 42%, p < 0.001).

CONCLUSION CONCLUSIONS

Baseline AARC score, MELD score, and the dynamic SURFASA score on day 3 can accurately identify early non-response to steroids in AIH-ACLF.

Identifiants

DOI: 10.1007/s12072-023-10482-4 PMID: 36790652

pubmed: 36790652

doi: 10.1007/s12072-023-10482-4

pii: 10.1007/s12072-023-10482-4

doi:

Substances chimiques

Prednisolone 9PHQ9Y1OLM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

989-999

Informations de copyright

Références

Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology. 2020. https://doi.org/10.1002/hep.31065

doi: 10.1002/hep.31065 pubmed: 32500593

Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? Liver Transpl. 2019;25(6):946–959. https://doi.org/10.1002/lt.25451

doi: 10.1002/lt.25451 pubmed: 30900368

Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEPReport. 2020;2:6. https://doi.org/10.1016/j.jhepr.2020.100149

doi: 10.1016/j.jhepr.2020.100149

Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–390. https://doi.org/10.1007/s12072-019-09946-3

doi: 10.1007/s12072-019-09946-3 pubmed: 31172417

Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61(4):876–882. https://doi.org/10.1016/j.jhep.2014.05.021

doi: 10.1016/j.jhep.2014.05.021 pubmed: 24842305

Zachou K, Arvaniti P, Azariadis K, et al. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res. 2019;49(1):96–104. https://doi.org/10.1111/hepr.13252

doi: 10.1111/hepr.13252 pubmed: 30248210

Anand L, Choudhury A, Bihari C, et al. Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy. Hepatology. 2019;70(2):587–596. https://doi.org/10.1002/hep.30205

doi: 10.1002/hep.30205 pubmed: 30113706

Fujiwara K, Yasui S, Yokosuka O. Autoimmune acute liver failure: an emerging etiology for intractable acute liver failure. Hepatol Int. 2013;7(2):335–346. https://doi.org/10.1007/s12072-012-9402-3

doi: 10.1007/s12072-012-9402-3 pubmed: 26201768

Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13(7):996–1003. https://doi.org/10.1002/lt.21036

doi: 10.1002/lt.21036 pubmed: 17370335

Joshita S, Yoshizawa K, Umemura T, et al. Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. J Gastroenterol. 2018;53(9):1079–1088. https://doi.org/10.1007/s00535-018-1444-4

doi: 10.1007/s00535-018-1444-4 pubmed: 29476251

Martin ED, Coilly A, Chazouillères O, et al. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score. J Hepatol. 2021;74(6):1325–1334. https://doi.org/10.1016/j.jhep.2020.12.033

doi: 10.1016/j.jhep.2020.12.033 pubmed: 33503489

Noguchi F, Chu P, sung, Yoshida A, et al. Early dynamics of meld scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.06.006

doi: 10.1016/j.cgh.2021.06.006 pubmed: 34102339

Shalimar N, Kedia S, Mahapatra SJ, et al. Severity and outcome of acute-on-chronic liver failure is dependent on the etiology of acute hepatic insults: analysis of 368 patients. J Clin Gastroenterol. 2017;51(8):734–741. https://doi.org/10.1097/MCG.0000000000000823

doi: 10.1097/MCG.0000000000000823 pubmed: 28296656

Sharma S, Agarwal S, Gopi S, et al. Determinants of outcomes in autoimmune hepatitis presenting as acute on chronic liver failure without extrahepatic organ dysfunction upon treatment with steroids. J Clin Exp Hepatol. 2021;11(2):171–180. https://doi.org/10.1016/j.jceh.2020.08.007

doi: 10.1016/j.jceh.2020.08.007 pubmed: 33746441

Granito A, Muratori P, Muratori L. Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis. J Hepatol. 2021. https://doi.org/10.1016/j.jhep.2021.06.035

doi: 10.1016/j.jhep.2021.06.035 pubmed: 34793869

Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53(2):517–526. https://doi.org/10.1002/hep.24080

doi: 10.1002/hep.24080 pubmed: 21274872

Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461–471. https://doi.org/10.1007/s12072-017-9816-z

doi: 10.1007/s12072-017-9816-z pubmed: 28856540